Ocugen (OCGN) Stock Price, News & Analysis

Company Overview

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders. Lead candidates include OCU400 for retinitis pigmentosa and OCU410 for wet age-related macular degeneration, each engineered to deliver functional genetic material to retinal cells. The company’s approach is rooted in adeno-associated viral (AAV) vector technology, which has the potential to enable single-administration treatments and durable therapeutic benefits for patients facing progressive vision loss.

On the vaccine front, Ocugen entered into a collaboration with India-based Bharat Biotech in mid-2020 to co-develop and commercialize the COVID-19 vaccine Covaxin in the United States and Canada. This partnership illustrates Ocugen’s ability to partner with established developers to bring critical vaccine candidates into North American regulatory pathways. The company is also exploring additional vaccine opportunities that may leverage its manufacturing and distribution networks.

Founded in 2014, Ocugen is led by President and Chief Executive Officer Dr. Shankar Musunuri, who co-founded the company with the goal of addressing conditions with limited or no treatment options. Under his leadership and that of an experienced management team, Ocugen continues to advance its pipeline through clinical trials and regulatory interactions, with a mission to deliver innovative therapies for patients worldwide.

Key Stats

• Today's Range: $1.34 to $1.44
• 50-Day Range: $1.18 to $1.67
• 52-Week Range: $0.98 to $2.73
• Volume: 3.90 million shs
• Average Volume: 4.62 million shs
• Market Capitalization: $457.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Moderate Buy

Ocugen Stock Analysis - MarketRank™

Ocugen scored higher than 36% of companies evaluated by MarketBeat, and ranked 724th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ocugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Ocugen has a consensus price target of $9.50, representing about 603.7% upside from its current price of $1.35.

Amount of Analyst Coverage

Ocugen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ocugen are expected to decrease in the coming year, from ($0.25) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocugen is -5.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocugen is -5.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

30.98% of the float of Ocugen has been sold short.

Short Interest Ratio / Days to Cover

Ocugen has a short interest ratio ("days to cover") of 21.55, which indicates bearish sentiment.

Change versus previous month

Short interest in Ocugen has recently increased by 0.32%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocugen does not currently pay a dividend.

Dividend Growth

Ocugen does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.21

News Sentiment

Ocugen has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Ocugen this week, compared to 6 articles on an average week.

Search Interest

Only 10 people have searched for OCGN on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.

MarketBeat Follows

11 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.

Company Ownership

• Score: 2.4 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $25,830.00 in company stock, which represents 0.0056% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Ocugen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,830.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

3.95% of the stock of Ocugen is held by insiders.

Percentage Held by Institutions

10.27% of the stock of Ocugen is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OCGN
• CIK: 1372299
• Web: ocugen.com
• Phone: (484) 328-4701
• Fax: 781-547-4452
• Employees: 80
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Ocugen: $9.50
• High Price Target: $11.00
• Low Price Target: $7.00
• Potential Upside/Downside: +603.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.85 million
• Net Margins: N/A
• Pretax Margin: -1,786.27%
• Return on Equity: -127,987.80%
• Return on Assets: -115.95%

Debt

• Debt-to-Equity Ratio: 4.17
• Current Ratio: 0.80
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: $4.41 million
• Price / Sales: 103.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -27.00

Miscellaneous

• Outstanding Shares: 339,110,000
• Free Float: 325,715,000
• Market Cap: $457.80 million
• Optionable: Optionable
• Beta: 2.21